Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHL Achilles Therapeutics	$1.48	$1.48	$0.63 ▼ $1.51	$60.83M	1.25	744,051 shs	N/A
ANNX Annexon	$2.31 +6.5%	$2.47	$1.28 ▼ $7.85	$253.84M	1.3	1.09 million shs	1.96 million shs
EDIT Editas Medicine	$2.80 +2.6%	$2.63	$0.91 ▼ $4.12	$251.78M	2.19	2.07 million shs	1.46 million shs
SCPH scPharmaceuticals	$4.85 +6.1%	$4.59	$1.94 ▼ $6.28	$258.50M	0.4	332,399 shs	289,254 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHL Achilles Therapeutics	0.00%	0.00%	0.00%	0.00%	+97.60%
ANNX Annexon	+6.45%	-5.33%	-6.85%	+9.48%	-60.91%
EDIT Editas Medicine	+2.56%	-7.59%	-19.08%	+80.65%	-31.37%
SCPH scPharmaceuticals	+6.13%	+5.43%	-9.68%	+46.53%	-10.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ANNX Annexon	2.7927 of 5 stars	3.4	3.0	0.0	0.0	3.1	2.5	0.0
EDIT Editas Medicine	4.2389 of 5 stars	3.1	4.0	0.0	4.3	1.5	2.5	0.6
SCPH scPharmaceuticals	4.5463 of 5 stars	3.5	5.0	0.0	4.2	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHL Achilles Therapeutics	0.00	N/A	N/A	N/A
ANNX Annexon	2.75	Moderate Buy	$12.50	441.13% Upside
EDIT Editas Medicine	2.23	Hold	$5.10	82.14% Upside
SCPH scPharmaceuticals	3.00	Buy	$14.00	188.66% Upside

Current Analyst Ratings Breakdown

Latest ACHL, EDIT, SCPH, and ANNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ANNX Annexon	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/15/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$3.00 ➝ $5.00
8/15/2025	ANNX Annexon	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $6.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	$3.49 per share	N/A
ANNX Annexon	N/A	N/A	N/A	N/A	$1.81 per share	N/A
EDIT Editas Medicine	$32.31M	7.79	N/A	N/A	$0.21 per share	13.33
SCPH scPharmaceuticals	$36.33M	7.12	N/A	N/A	($0.40) per share	-12.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHL Achilles Therapeutics	-$69.67M	-$1.65	N/A	N/A	N/A	N/A	-54.45%	-47.68%	N/A
ANNX Annexon	-$138.20M	-$1.29	0.00	N/A	N/A	N/A	-70.04%	-57.67%	N/A
EDIT Editas Medicine	-$237.09M	-$2.85	N/A	N/A	N/A	-608.88%	-200.25%	-68.57%	11/3/2025 (Estimated)
SCPH scPharmaceuticals	-$85.15M	-$1.81	0.00	N/A	N/A	-183.55%	-1,647.86%	-71.76%	N/A

Latest ACHL, EDIT, SCPH, and ANNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ANNX Annexon	-$0.36	-$0.34	+$0.02	-$0.34	N/A	N/A
8/12/2025	Q2 2025	EDIT Editas Medicine	-$0.41	-$0.63	-$0.22	-$0.63	$1.81 million	$3.58 million
8/7/2025	Q2 2025	SCPH scPharmaceuticals	-$0.30	-$0.34	-$0.04	-$0.34	$15.41 million	$16.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
SCPH scPharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHL Achilles Therapeutics	N/A	6.04	6.04
ANNX Annexon	N/A	5.67	7.99
EDIT Editas Medicine	N/A	2.77	2.77
SCPH scPharmaceuticals	3.86	3.85	3.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHL Achilles Therapeutics	56.38%
ANNX Annexon	N/A
EDIT Editas Medicine	71.90%
SCPH scPharmaceuticals	89.52%

Insider Ownership

Company	Insider Ownership
ACHL Achilles Therapeutics	5.38%
ANNX Annexon	11.87%
EDIT Editas Medicine	2.10%
SCPH scPharmaceuticals	4.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHL Achilles Therapeutics	250	41.10 million	38.89 million	Not Optionable
ANNX Annexon	60	109.89 million	96.84 million	Optionable
EDIT Editas Medicine	230	89.92 million	88.03 million	Optionable
SCPH scPharmaceuticals	30	53.30 million	50.75 million	Optionable

ACHL, EDIT, SCPH, and ANNX Headlines

Recent News About These Companies

scPharmaceuticals, Inc. (NASDAQ:SCPH) Short Interest Down 36.1% in July

August 21 at 11:17 AM | marketbeat.com

scPharmaceuticals receives Notices of Allowance from USPTO for SCP-111

August 14, 2025 | msn.com

scPharmaceuticals Q2 2025 Earnings Call Highlights Growth

August 14, 2025 | theglobeandmail.com

scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111

August 14, 2025 | globenewswire.com

scPharmaceuticals management to meet with Craig-Hallum

August 12, 2025 | msn.com

scPharmaceuticals, Inc. (NASDAQ:SCPH) Shares Acquired by King Luther Capital Management Corp

August 12, 2025 | marketbeat.com

Wall Street Zen Upgrades scPharmaceuticals (NASDAQ:SCPH) to "Hold"

August 10, 2025 | marketbeat.com

H.C. Wainwright Reaffirms Their Buy Rating on scPharmaceuticals (SCPH)

August 9, 2025 | theglobeandmail.com

SCPH Revenue Up 99%

August 9, 2025 | aol.comA

ScPharmaceuticals anticipates meaningful Q3 nephrology contribution as FUROSCIX shipments rise 45% in Q2 2025

August 9, 2025 | msn.com

scPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025 | globenewswire.com

Shareholders in scPharmaceuticals (NASDAQ:SCPH) are in the red if they invested five years ago

August 5, 2025 | uk.finance.yahoo.com

scPharmaceuticals (SCPH) to Release Earnings on Thursday

August 5, 2025 | marketbeat.com

scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025

July 31, 2025 | globenewswire.com

scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?

July 25, 2025 | zacks.com

With 42% stake, scPharmaceuticals Inc. (NASDAQ:SCPH) seems to have captured institutional investors' interest

June 12, 2025 | finance.yahoo.com

scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025

May 22, 2025 | seekingalpha.com

scPharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

May 16, 2025 | finance.yahoo.com

scPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2025 Earnings Call Transcript

May 16, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHL, EDIT, SCPH, and ANNX Company Descriptions

Achilles Therapeutics NASDAQ:ACHL

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Annexon NASDAQ:ANNX

$2.31 +0.14 (+6.45%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.30 -0.01 (-0.43%)

As of 08/22/2025 07:52 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Editas Medicine NASDAQ:EDIT

$2.80 +0.07 (+2.56%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.80 +0.01 (+0.18%)

As of 08/22/2025 07:51 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

scPharmaceuticals NASDAQ:SCPH

$4.85 +0.28 (+6.13%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.85 0.00 (0.00%)

As of 08/22/2025 04:04 PM Eastern

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time